Comparative study on the efficacy of sulbactam·ampicillin and ampicillin in respiratory tract infections

Kotaro Oizumi, Akira Saito, Akira Suzuki, Yohmei Hiraga, Kazuo Takebe, Masao Tamura, Hiroyuki Kobayashi, Atsushi Saito, Ippei Fujimori, Fumio Miki, Rinzo Soejima, Kohei Hara, Keizo Matsumoto, Kiyoshi Konno, Akihiko Homma, Matsumi Tosaka, Tomofumi Igarashi, Katsunori Kasahara, Sohkichi Onodera, Nobuhiro SasakiYuji Ikeda, Akira Saito, Akira Suzuki, Yasuto Honnda, Masumi Tomizawa, Yohmei Hiraga, Mituhide Ohmichi, Ichiro Nakayama, Akio Hirayama, Susumu Isokawa, Kyuichiro Sekine, Susumu Itoh, Hirotoshi Nishizawa, Morikuni Abe, Choei Itoh, Keisuke Takeuchi, Hajime Watanabe, Tsuyoshi Kikuiri, Tadashi Murakami, Kazuo Takebe, Katsuhiro Okamoto, Morio Sagara, Toyoichi Tamura, Katsumi Endoh, Masashi Yoneda, Osamu Uehara, Tadashi Miyasawa, Mitsuo Nakamura, Kiyoshi Kawamorita, Masao Tamura, Takashi Itoh, Nobuhisa Satoh, Kazuo Tanifuji, Hiroshi Kuramistu, Kohtaro Itakura, Tsukasa Yoshida, Masayuki Yoshizawa, Mamoru Furuta, Masato Hayashi, Kazuo Satoh, Kiichi Kaishio, Noboru Asabu, Saburo Shindoh, Kohsaku Nagai, Kiyoshi Konno, Kotaro Oizumi, Akira Watanabe, Hiroyuki Nakai, Junichi Saito, Tokuji Honda, Fumio Ariji, Teruo Hasuike, Moriaki Nishina, Masayuki Itoh, Shigeru Tamari, Eiju Umehara, Izumi Hayashi, Tsuguji Itoh, Yoshiyuki Ando, Yasushi Ueda, Atsushi Saito, Tadashi Miyahara, Hiroyuki Kobayashi, Yasuyuki Sano, Yasufumi Miyamoto, Ippei Fujimori, Yoshio Kobayashi, Shigeo Takizawa, Fumio Miki, Rinzo Soejima, Yoshihito Niki, Toshiro Oda, Kohei Hara, Keizo Matsumoto, Toshiaki Hayashi, Harumi Shishido, Kaoru Shimada, Mieko Gotoh, Nobuya Ogawa

    Research output: Contribution to journalArticlepeer-review

    2 Citations (Scopus)

    Abstract

    A multi-center double-blind three-group comparison study of sulbactam·ampicillin (SBT·ABPC) vs. ampicillin (ABPC) was performed to evaluate their efficacy, safety and usefulness in the treament of patients with respiratory tract infections. The clinical efficacy rated by Investigators' Judgment Committee was compared among three dosage groups of 3g SBT·ABPC, 6g SBT·ABPC and 4g ABPC. In the patients with pulmonary parenchymal infections, the efficacy rate was 82.5%, 92.1% and 94.6%, respectively. In chronic respiratory tract infections, that rate was 86.7%, 81.6% and 82.1%, respectively. All of these three groups showed excellent efficacy rates, and there were no significant differences among them. The bacterial eradication rate was 93.2%, 83.7% and 85.4% respectively, suggesting that there were no significant differences in the bacteriological efficacy among the three dosage groups. The MICs, determined at a central laboratory, indicated that almost all the strains were sensitive to SBT·ABPC and many to ABPC alone. The MICs of ABPC were 25 μg/ml and above against 13 strains, whereas those of SBT·ABPC were 2-to 5-fold lower. All dosage groups exhibited high usefulness rates with a low incidence of side effects and parameter abnormalities in laboratory tests, suggesting no significant differences in safety and usefulness. The results obtained in this study indicate that SBT·ABPC is useful in the treatment of patients with respiratory tract infections.

    Original languageEnglish
    Pages (from-to)272-291
    Number of pages20
    JournalChemotherapy
    Volume36
    DOIs
    Publication statusPublished - 1988

    ASJC Scopus subject areas

    • Pharmacology (medical)
    • Infectious Diseases
    • Pharmacology
    • Drug Discovery
    • Oncology

    Fingerprint Dive into the research topics of 'Comparative study on the efficacy of sulbactam·ampicillin and ampicillin in respiratory tract infections'. Together they form a unique fingerprint.

    Cite this